News for Healthier Living

Beyond High-Dose IL-2: A novelTIL Expansion Platform Improves Safety and Efficacyof TIL Therapyina Preclinical Study

Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has emerged as a powerful immunotherapy for solid tumors, yet its broader application is constrained by reliance on high-dose interleukin-2 (IL-2), a cytokine that activates T cells but also drives T-cell exhaustion and causes severe toxicity.

July 3, 2026


July 3 2026

July 2 2026

July 1 2026

June 30 2026

June 29 2026

June 26 2026

June 25 2026

June 24 2026

June 23 2026

June 22 2026

June 21 2026